The growing literature on CDI antimicrobial treatment and novel treatment approaches, such as fecal microbiota transplantation and toxin-binding monoclonal antibodies, prompted the ESCMID study group on C. difficile to update the 2014 treatment guidance document for CDI in adults.
|